8-K filing — Zura Bio Ltd (ZURA)
Filed: 2026-08-17 AccNo: 0001104659-26-097526 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22
Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $15 to $22.
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20
Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.
Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 23.53 percent decrease over losses of $(0.17) per share from the same